Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
DiaMedica Therapeutics Inc
NASDAQ DMAC
Data sourced from
and
and
DiaMedica Therapeutics Inc Current Liabilities 3 year CAGR for the quarter ending March 31, 2024: 30.48%
DiaMedica Therapeutics Inc Current Liabilities 3 year CAGR is 30.48% for the quarter ending March 31, 2024, a -31.31% change year over year. Current Liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
DiaMedica Therapeutics Inc Current Liabilities for the quarter ending March 31, 2023 was USD 2.81 M, a 96.23% change year over year.
-
DiaMedica Therapeutics Inc Current Liabilities for the quarter ending March 31, 2022 was USD 1.43 M, a 21.73% change year over year.
-
DiaMedica Therapeutics Inc Current Liabilities for the quarter ending March 31, 2021 was USD 1.18 M, a 25.99% change year over year.
-
DiaMedica Therapeutics Inc Current Liabilities for the quarter ending March 31, 2020 was USD 935.00 K, a -34.39% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DMAC
| CEO | Mr. Dietrich John Pauls MBA |
| IPO Date | Jan. 4, 2008 |
| Location | United States |
| Headquarters | Two Carlson Parkway, Minneapolis, MN, United States, 55447 |
| Employees | 18 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Key trends
Similar companies
Milestone Pharmaceuticals Inc
NA
NA
Centessa Pharmaceuticals PLC ADR
NA
NA
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email